Advances in our understanding of genetic markers and targeted therapies for pediatric LCH

References

• Allen CE, Merad M, McClain KL. Langerhans-Cell Histiocytosis. Longo DL, ed. N Engl J Med. 2018;379(9):856–868. doi: 10.1056/NEJMra1607548
   PubMed Web of Science ®Google Scholar
• Gadner H, Minkov M, Grois N, et al. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. ClinicalTrials Gov) (Blood. 2013;121(25):5006–5014. doi: 10.1182/blood-2012-09-455774
   Google Scholar
• Arceci RJ, Brenner MK, Pritchard J. Controversies and new approaches to treatment of Langerhans cell histiocytosis. Hematol Oncol Clin North Am. 1998;12(2):339–357. doi: 10.1016/S0889-8588(05)70514-1
   PubMed Web of Science ®Google Scholar
• Zhang W, Liu HT, Tu H. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 2002;12(1):9–18. Available from: http://www.cell-research.com
   PubMed Web of Science ®Google Scholar
• Dhillon AS, Hagan S, Rath O, et al. MAP kinase signalling pathways in cancer. Oncogene. 2007;26(22):3279–3290. doi: 10.1038/sj.onc.1210421
   PubMed Web of Science ®Google Scholar
• Braicu C, Buse M, Busuioc C, et al. A comprehensive review on MAPK: a promising therapeutic target in cancer. Cancers (Basel). 2019;11(10):1618. doi: 10.3390/cancers11101618
   PubMed Web of Science ®Google Scholar
• Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116(11):1919–1923. doi: 10.1182/blood-2010-04-279083
   PubMed Web of Science ®Google Scholar
• Bubolz AM, Weissinger SE, Stenzinger A, et al. Potential clinical implications of BRAF mutations in histiocytic proliferations. Oncotarget. 2014;5(12):4060. Available from: www.impactjournals.com/oncotarget
   PubMedGoogle Scholar
• Berres ML, Lim KPH, Peters T, et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2014;211(4):669–683. doi: 10.1084/jem.20130977
   PubMed Web of Science ®Google Scholar
• Kemps PG, Zondag TCE, Arnardóttir HB, et al. Clinicogenomic associations in childhood Langerhans cell histiocytosis: an international cohort study. Blood Adv. 2023;7(4):664–679. doi: 10.1182/bloodadvances.2022007947
   PubMed Web of Science ®Google Scholar
• Chakraborty R, Hampton OA, Shen X, et al. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood. 2014;124(19):3007–3015. doi: 10.1182/blood-2014-05-577825
   PubMed Web of Science ®Google Scholar
• Diamond EL, Durham BH, Haroche J, et al. Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov. 2016;6(2):154–165. doi: 10.1158/2159-8290.CD-15-0913
   PubMed Web of Science ®Google Scholar
• Cai J, Huang X, Yin M, et al. A novel fusion gene PLEKHA6-NTRK3 in Langerhans cell histiocytosis. Int J Cancer. 2019;144(1):117–124. doi: 10.1002/ijc.31636
   PubMed Web of Science ®Google Scholar
• Liu R, Guo Y, Han L, et al. Somatic ARAF mutations in pediatric Langerhans cell histiocytosis: clinicopathologic, genetic and functional profiling. Clin Exp Med. 2023;23(8):5269–5279. doi: 10.1007/s10238-023-01134-w
   PubMed Web of Science ®Google Scholar
• Sahm F, Capper D, Preusser M, et al. BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood. 2012;120(12):e28–34. doi: 10.1182/blood-2012-06-429597
   PubMed Web of Science ®Google Scholar
• Nikolaev SI, Rimoldi D, Iseli C, et al. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet. 2012;44(2):133–139. doi: 10.1038/ng.1026
   Web of Science ®Google Scholar
• Brown NA, V FL, Betz BL, et al. Brief report MYELOID NEOPLASIA high prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. Blood. 2014;124(10):1655–1658. doi: 10.1182/blood-2014-05-577361
   PubMed Web of Science ®Google Scholar
• Liu W, Jie LH, Ya WW, et al. Multisystem ALK-positive histiocytosis: a multi-case study and literature review. Orphanet J Rare Dis. 2023;18(1):1–12. doi: 10.1186/s13023-023-02649-x
   PubMed Web of Science ®Google Scholar
• Lee LH, Gasilina A, Roychoudhury J, et al. Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes. JCI Insight. 2017;2(3):e89473. doi: 10.1172/jci.insight.89473
   PubMed Web of Science ®Google Scholar
• Nelson DS, van Halteren A, Quispel WT, et al. MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis. Genes Chromosomes Cancer. 2015;54(6):361–368. doi: 10.1002/gcc.22247
   PubMed Web of Science ®Google Scholar
• Kansal R, Quintanilla-Martinez L, Datta V, et al. Identification of the V600D mutation in Exon 15 of the BRAF oncogene in congenital, benign Langerhans cell histiocytosis. Genes Chromosomes Cancer. 2013;52(1):99–106. doi: 10.1002/gcc.22010
   PubMed Web of Science ®Google Scholar
• Diamond EL, Durham BH, Ulaner GA, et al. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019;567(7749):521–524. doi: 10.1038/s41586-019-1012-y
   PubMed Web of Science ®Google Scholar
• Chakraborty R, Burke TM, Hampton OA, et al. Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis. Blood. 2016;128(21):2533–2537. doi: 10.1182/blood-2016-08-733790
   PubMed Web of Science ®Google Scholar
• Hechtman JF. NTRK insights: best practices for pathologists. Mod Pathol. 2022;35(3):298–305. doi: 10.1038/s41379-021-00913-8
   PubMed Web of Science ®Google Scholar
• Umphress B, Kuhar M, Kowal R, et al. NTRK expression is common in xanthogranuloma and is associated with the solitary variant. J Cutan Pathol. 2023;50(11):991–1000. doi: 10.1111/cup.14510
   PubMed Web of Science ®Google Scholar
• Haroche J, Donadieu J, Emile JF. Common cancer-associated PIK3CA activating mutations rarely occur in Langerhans cell histiocytosis. Blood. 2015;125(15):2448–2449. doi: 10.1182/blood-2015-01-625491
   PubMed Web of Science ®Google Scholar
• Kemps PG, Picarsic J, Durham BH, et al. ALK-Positive histocytosis. Blood. 2022;139(2):256–280. Available from: http://ashpublications.org/blood/article-pdf/139/2/256/1863353/bloodbld2021013338.pdf
   PubMedGoogle Scholar
• Chang KTE, Tay AZE, Kuick CH, et al. ALK-positive histiocytosis: an expanded clinicopathologic spectrum and frequent presence of KIF5B-ALK fusion. Mod Pathol. 2019;32(5):598–608. doi: 10.1038/s41379-018-0168-6
   PubMed Web of Science ®Google Scholar
• Ravindran A, Goyal G, Failing JJ, et al. Florid dermatopathic lymphadenopathy—A morphological mimic of Langerhans cell histiocytosis. Clin Case Rep. 2018;6(8):1637–1638. doi: 10.1002/ccr3.1663
   PubMedGoogle Scholar
• Paredes SEY, Almeida LY, Trevisan GL, et al. Immunohistochemical characterization of immune cell infiltration in paediatric and adult Langerhans cell histiocytosis. Scand J Immunol. 2020;92(6):e12950. doi: 10.1111/sji.12950
   PubMed Web of Science ®Google Scholar
• Shanmugam V, Craig JW, Hornick JL, et al. Cyclin D1 is expressed in neoplastic cells of Langerhans cell histiocytosis but not reactive Langerhans cell proliferations. Am J Surg Pathol. 2017;41(10):1390–1396. doi: 10.1097/PAS.0000000000000897
   PubMed Web of Science ®Google Scholar
• Ben Rejeb S, Charfi L, Sahraoui G, et al. Cyclin D1: potential utility as marker for Langerhans cell histiocytosis. J Immunoassay Immunochem. 2021;42(4):370–379. doi: 10.1080/15321819.2020.1870132
   PubMedGoogle Scholar
• Ballester LY, Cantu MD, Lim KPH, et al. The use of BRAF V600E mutation-specific immunohistochemistry in pediatric Langerhans cell histiocytosis. Hematol Oncol. 2018;36(1):307–315. doi: 10.1002/hon.2388
   PubMed Web of Science ®Google Scholar
• Donadieu J, Larabi IA, Tardieu M, et al. Vemurafenib for refractory multisystem Langerhans cell histiocytosis in children: an international observational study. J Clin Oncol. 2019;37(31):2857–2865. doi: 10.1200/JCO.19.00456
   PubMed Web of Science ®Google Scholar
• Schwentner R, Kolenová A, Jug G, et al. Longitudinal assessment of peripheral blood BRAFV600E levels in patients with Langerhans cell histiocytosis. Pediatr Res. 2019;85(6):856–864. doi: 10.1038/s41390-018-0238-y
   PubMed Web of Science ®Google Scholar
• Héritier S, Hélias-Rodzewicz Z, Lapillonne H, et al. Circulating cell-free BRAFV600E as a biomarker in children with Langerhans cell histiocytosis. Br J Haematol. 2017;178(3):457–467. doi: 10.1111/bjh.14695
   PubMed Web of Science ®Google Scholar
• Simko SJ, Garmezy B, Abhyankar H, et al. Differentiating skin-limited and multisystem Langerhans cell histiocytosis. J Paediatr. 2014;165(5):990–996. doi: 10.1016/j.jpeds.2014.07.063
   PubMed Web of Science ®Google Scholar
• Héritier S, Emile JF, Barkaoui MA, et al. BRAF mutation correlates with high-risk Langerhans cell histiocytosis and increased resistance to first-line therapy. J Clin Oncol. 2016;34(25):3023–3030. doi: 10.1200/JCO.2015.65.9508
   PubMed Web of Science ®Google Scholar
• Donadieu J, Bernard F, Van Noesel M, et al. Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study. Blood. 2015;126(12):1415–1423. doi: 10.1182/blood-2015-03-635151
   PubMed Web of Science ®Google Scholar
• Simko SJ, Tran HD, Jones J, et al. Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease. Pediatr Blood Cancer. 2014;61(3):479–487. doi: 10.1002/pbc.24772
   PubMed Web of Science ®Google Scholar
• Evseev D, Osipova D, Kalinina I, et al. Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E–positive LCH. Blood Adv. 2023;7(18):5246–5257. doi: 10.1182/bloodadvances.2022009067
   PubMed Web of Science ®Google Scholar
• Haroche J, Cohen-Aubart F, Emile JF, et al. Plenary paper dramatic efficacy of vemurafenib in both multisystemic and refractory erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 2013;121(9):1495–1500. doi: 10.1182/blood-2012-07-446286
   PubMed Web of Science ®Google Scholar
• Héritier S, Jehanne M, Leverger G, et al. Vemurafenib use in an infant for high-risk Langerhans cell histiocytosis. JAMA Oncol. 2015;1(6):836–838. doi: 10.1001/jamaoncol.2015.0736
   PubMed Web of Science ®Google Scholar
• Kolenová A, Schwentner R, Jug G, et al. Targeted inhibition of the MAPK pathway: emerging salvage option for progressive life-threatening multisystem LCH. Blood Adv. 2017;1(6):352–356. doi: 10.1182/bloodadvances.2016003533
   PubMed Web of Science ®Google Scholar
• Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373(8):726–736. doi: 10.1056/nejmoa1502309
   PubMed Web of Science ®Google Scholar
• Mohapatra D, Gupta AK, Haldar P, et al. Efficacy and safety of vemurafenib in Langerhans cell histiocytosis (LCH): a systematic review and meta-analysis. Pediatr Hematol Oncol. 2023;40(1):86–97. doi: 10.1080/08880018.2022.2072986
   PubMed Web of Science ®Google Scholar
• Whitlock JA, Geoerger B, Dunkel IJ, et al. Dabrafenib, alone or in combination with trametinib, in BRAF V600-mutated pediatric Langerhans cell histiocytosis. Blood Adv. 2023;7(15):3806–3815. doi: 10.1182/bloodadvances.2022008414
   PubMed Web of Science ®Google Scholar
• FDA grants accelerated approval to dabrafenib in combination with trametinib for unresectable or metastatic solid tumors with BRAF V600E mutation | FDA. [cited 2023 Oct 17]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid
   Google Scholar
• Ascierto PA, Dreno B, Larkin J, et al. 5-year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation-positive advanced melanoma: extended follow-up of the coBRIM study. Clin Cancer Res. 2021;27(19):5225–5235. doi: 10.1158/1078-0432.CCR-21-0809
   PubMed Web of Science ®Google Scholar
• Mazor RD, Weissman R, Luckman J, et al. Dual BRAF/MEK blockade restores CNS responses in BRAF-mutant erdheim-Chester disease patients following BRAF inhibitor monotherapy. Neurooncol Adv. 2020;2(1):vdaa024. doi: 10.1093/noajnl/vdaa024
   PubMedGoogle Scholar
• Papapanagiotou M, Griewank KG, Hillen U, et al. Trametinib-Induced Remission of an MEK1 -mutated Langerhans cell histiocytosis. JCO Precis Oncol. 2017 1;(1):1–5. doi: 10.1200/po.16.00070
   PubMedGoogle Scholar
• Vieira GC, Carvalho LD, Do Carmo CBC, et al. Rosai Dorfman’s disease with MAP2K1 mutation refractory to chemotherapy with complete response to MEK inhibitor therapy: a case report. Blood. 2022;140(Supplement 1):11163–11163. doi: 10.1182/blood-2022-159767
   Google Scholar
• Satoh T, Smith A, Sarde A, et al. B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease. PLOS ONE. 2012;7(4):e33891. doi: 10.1371/journal.pone.0033891
   PubMed Web of Science ®Google Scholar
• FDA approves oral MEK inhibitor cobimetinib for histiocytic neoplasms - the ASCO Post. [cited 2024 Feb 21]. Available from: https://ascopost.com/issues/december-10-2022/fda-approves-oral-mek-inhibitor-cobimetinib-for-histiocytic-neoplasms/
   Google Scholar
• Eder SK, Schwentner R, Ben SP, et al. Vemurafenib acts as a molecular on-off switch governing systemic inflammation in Langerhans cell histiocytosis. Blood Adv. 2022;6(3):970–975. doi: 10.1182/bloodadvances.2021005442
   PubMed Web of Science ®Google Scholar
• Phillips M, Allen C, Gerson P, et al. Comparison of FDG-PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosis. Pediatr Blood Cancer. 2009;52(1):97–101. doi: 10.1002/PBC.21782
   PubMed Web of Science ®Google Scholar
• Diamond EL, Subbiah V, Craig Lockhart A, et al. Vemurafenib for BRAF V600-mutant erdheim-Chester disease and Langerhans cell histiocytosis analysis of data from the histology-independent, phase 2, open-label VE-BASKET study. JAMA Oncol. 2018;4(3):384–388. doi: 10.1001/jamaoncol.2017.5029
   PubMed Web of Science ®Google Scholar
• Eckstein OS, Visser J, Rodriguez-Galindo C, et al. Clinical responses and persistent BRAF V600E1 blood cells in children with LCH treated with MAPK pathway inhibition. Blood. 2019;133(15):1691–1694. doi: 10.1182/blood-2018-10-878363
   PubMed Web of Science ®Google Scholar
• McClain KL, Picarsic J, Chakraborty R, et al. CNS Langerhans cell histiocytosis: common hematopoietic origin for LCH-associated neurodegeneration and mass lesions. Cancer. 2018;124(12):2607–2620. doi: 10.1002/cncr.31348
   PubMed Web of Science ®Google Scholar
• Cohen Aubart F, Emile JF, Carrat F, et al. Targeted therapies in 54 patients with erdheim-Chester disease, including follow-up after interruption (the LOVE study). Blood. 2017;130(11):1377–1380. doi: 10.1182/BLOOD-2017-03-771873
   PubMed Web of Science ®Google Scholar
• Reiner AS, Durham BH, Yabe M, et al. Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms. Br J Haematol. 2023;203(3):389–394. doi: 10.1111/bjh.18964
   PubMed Web of Science ®Google Scholar
• Cournoyer E, Ferrell J, Sharp S, et al. Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders. Haematologica. [cited 2023 Sep 21]. doi: 10.3324/haematol.2023.283295
   Web of Science ®Google Scholar
• Atallah E, Schiffer CA. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom? Haematologica. 2020;105(12):2738–2745. doi: 10.3324/haematol.2019.242891
   PubMed Web of Science ®Google Scholar
• Bouffet E, Hansford JR, Garrè ML, et al. Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations. N Engl J Med. 2023;389(12):1108–1120. doi: 10.1056/NEJMoa2303815
   PubMed Web of Science ®Google Scholar
• Castillejo Becerra CM, Smith WM, Dalvin LA. Ophthalmic adverse effects of BRAF inhibitors. Eur J Ophthalmol. 2023;33(2):1224–1231. doi: 10.1177/11206721221132872
   Web of Science ®Google Scholar
• Goodman RS, Di Guardo L, Maurichi A, et al. Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma. European Journal Of Cancer. 2024;194:194. doi: 10.1016/j.ejca.2023.113354
   Web of Science ®Google Scholar
• Cohen Aubart F, Idbaih A, Emile JF, et al. Histiocytosis and the nervous system: from diagnosis to targeted therapies. Neuro Oncol. 2021;23(9):1433–1446. doi: 10.1093/neuonc/noab107
   PubMed Web of Science ®Google Scholar
• Héritier S, Barkaoui MA, Miron J, et al. Incidence and risk factors for clinical neurodegenerative Langerhans cell histiocytosis: a longitudinal cohort study. Br J Haematol. 2018;183(4):608–617. doi: 10.1111/bjh.15577
   PubMed Web of Science ®Google Scholar
• Wilk CM, Cathomas F, Török O, et al. Circulating senescent myeloid cells infiltrate the brain and cause neurodegeneration in histiocytic disorders. Immunity. 2023;56(12):2790–2802.e6. doi: 10.1016/j.immuni.2023.11.011
   PubMed Web of Science ®Google Scholar
• Mass E, Jacome-Galarza CE, Blank T, et al. A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease. Nature. 2017;549(7672):389–393. doi: 10.1038/nature23672
   PubMed Web of Science ®Google Scholar
• Euskirchen P, Haroche J, Emile JF, et al. Complete remission of critical neurohistiocytosis by vemurafenib. Neurol(r) Neuroimmunol Neuroinflammation. 2015;2(2):e78. doi: 10.1212/NXI.0000000000000078
   PubMed Web of Science ®Google Scholar
• Kilburn LB, Khuong-Quang DA, Hansford JR, et al. The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. Nat Med. 2024;30(1):207–217. doi: 10.1038/s41591-023-02668-y
   PubMedGoogle Scholar
• Héritier S, Hélias-Rodzewicz Z, Chakraborty R, et al. New somatic BRAF splicing mutation in Langerhans cell histiocytosis. Mol Cancer. 2017;16(1). doi: 10.1186/s12943-017-0690-z
   PubMedGoogle Scholar
• Proietti I, Skroza N, Bernardini N, et al. Mechanisms of acquired BRAF inhibitor resistance in melanoma: a systematic review. Cancers (Basel). 2020;12(10):1–29. doi: 10.3390/cancers12102801
   Web of Science ®Google Scholar
• Sengal A, Velazquez J, Hahne M, et al. Overcoming T-cell exhaustion in LCH: PD-1 blockade and targeted MAPK inhibition are synergistic in a mouse model of LCH. Blood. 2021;137(13):1777–1791. Available from: http://ashpublications.org/blood/article-pdf/137/13/1777/1803993/bloodbld2020005867.pdf
   PubMed Web of Science ®Google Scholar
• Bigenwald C, Le Berichel J, Wilk CM, et al. BRAF V600E-induced senescence drives Langerhans cell histiocytosis pathophysiology. Nat Med. 2021;27(5):851–861. doi: 10.1038/s41591-021-01304-x
   PubMed Web of Science ®Google Scholar
• Gianfreda D, Nicastro M, Galetti M, et al. Sirolimus plus prednisone for Erdheim-Chester disease: an open-label trial. Blood. 2015;126(10):1163–1171. doi: 10.1182/BLOOD-2015-01-620377
   PubMed Web of Science ®Google Scholar
• Golwala ZM, Taur P, Pandrowala A, et al. Sirolimus-A targeted therapy for Rosai-Dorfman disease. Pediatr Blood Cancer. 2019;66(12):e27994. doi: 10.1002/PBC.27994
   PubMed Web of Science ®Google Scholar
• Feng S, Han L, Yue M, et al. Frequency detection of BRAF V600E mutation in a cohort of pediatric Langerhans cell histiocytosis patients by next-generation sequencing. Orphanet J Rare Dis. 2021;16(1):272. doi: 10.1186/s13023-021-01912-3
   PubMed Web of Science ®Google Scholar
• Nelson DS, Quispel W, Badalian-Very G, et al. Brief report MYELOID NEOPLASIA Somatic activating ARAF mutations in Langerhans cell histiocytosis. Blood. 2014;123(20):3152–3155. doi: 10.1182/blood-2013-06-511139
   PubMed Web of Science ®Google Scholar
• Chan JKC, Lamant L, Algar E, et al. ALK+ histiocytosis: a novel type of systemic histiocytic proliferative disorder of early infancy. Blood. 2008;112(7):2965–2968. doi: 10.1182/blood-2008-03-147017
   PubMed Web of Science ®Google Scholar